Texas Yale Capital Corp’s GSK GSK Stock Holding History

Texas Yale Capital Corp’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,808	Closed	-$262K	–	462
2022 Q2	$262K	Buy	4,808 +184	+4%	+$10.2K	0.02%	379
2022 Q1	$252K	Buy	4,624 +376	+9%	+$20.4K	0.01%	398
2021 Q4	$234K	Buy	4,248 +56	+1%	+$2.91K	0.01%	411
2021 Q3	$200K	Buy	+4,192	New	+$211K	0.01%	431
2017 Q4	–	Sell	-7,398	Closed	-$375K	–	443
2017 Q3	$375K	Buy	7,398 +238	+3%	+$12.1K	0.03%	353
2017 Q2	$386K	Hold	7,160	–	–	0.03%	344
2017 Q1	$377K	Hold	7,160	–	–	0.03%	345
2016 Q4	$345K	Sell	7,160 -7,720	-52%	-$381K	0.03%	350
2016 Q3	$802K	Sell	14,880 -4,000	-21%	-$219K	0.08%	232
2016 Q2	$1.02M	Buy	18,880 +8,560	+83%	+$451K	0.1%	184
2016 Q1	$523K	Hold	10,320	–	–	0.05%	287
2015 Q4	$521K	Hold	10,320	–	–	0.05%	286
2015 Q3	$496K	Buy	10,320 +1,840	+22%	+$95.8K	0.05%	303
2015 Q2	$441K	Buy	8,480 +4,000	+89%	+$225K	0.04%	357
2015 Q1	$258K	Hold	4,480	–	–	0.02%	429
2014 Q4	$239K	Hold	4,480	–	–	0.02%	427
2014 Q3	$257K	Hold	4,480	–	–	0.02%	387
2014 Q2	$299K	Buy	4,480 +240	+6%	+$16.2K	0.04%	314
2014 Q1	$283K	Hold	4,240	–	–	0.04%	306
2013 Q4	$283K	Hold	4,240	–	–	0.04%	253
2013 Q3	$266K	Hold	4,240	–	–	0.04%	257
2013 Q2	$265K	Buy	+4,240	New	+$269K	0.05%	236

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Texas Yale Capital Corp's GSK Position: Q3 2022 in Review

Texas Yale Capital Corp sold out of GSK (GSK) in Q3 2022, closing a stake of 4,808 shares — an estimated $262K sold.

Texas Yale Capital Corp first reported a position in GSK in Q2 2013 and held it in 22 quarters. The position peaked at $1.02M in Q2 2016. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

Texas Yale Capital Corp reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
Texas Yale Capital Corp sold 4,808 GSK shares in Q3 2022, an estimated $262K.
Texas Yale Capital Corp first reported a position in GSK in Q2 2013 and held it in 22 quarters.
Texas Yale Capital Corp's GSK position peaked at $1.02M in Q2 2016.
742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Texas Yale Capital Corp's 13F filing for Q3 2022, filed 8 Nov 2022.